Investor Intelligence

10 Early-Stage Diagnostics Investors Active in Europe

Investors with relevant activity across molecular diagnostics, medical imaging, liquid biopsy, prenatal ultrasound and point-of-care testing.

Published 24 September 2026

Diagnostics
Medtech
Molecular Diagnostics
Medical Imaging
Europe

Early-stage diagnostics in Europe is attracting capital from healthcare specialists, deep-tech funds and AI investors. Recent rounds span molecular testing, quantitative imaging, liquid biopsy, prenatal ultrasound and surgical imaging, showing that diagnostics is being financed across several technology and clinical models rather than one narrow category.

DealBio selected ten investors to feature based on recent, relevant diagnostics activity in Europe. The list is not a ranking.

Sofinnova Partners

European life-sciences investor with dedicated strategies spanning biotech, medical devices and digital medicine.

Stage: Seed · Series A
Sector / Focus: Medtech · Diagnostics · Digital Medicine
Investment markets: France · United Kingdom · Europe
Investor type: VC

Relevant investment

Sofinnova Partners participated in BrightHeart’s €11 million Series A in January 2026. BrightHeart is developing AI software for prenatal ultrasound that checks scan completeness and analyses fetal-heart views for signs of severe congenital heart defects, giving Sofinnova direct exposure to image-based diagnostics embedded in routine clinical workflows.

Air Street Capital

AI-focused VC investing in companies built around machine learning and data-intensive technology.

Stage: Seed · Series A
Sector / Focus: AI · Molecular Diagnostics · Precision Oncology
Investment markets: Switzerland · Europe
Investor type: VC

Relevant investment

Air Street Capital is an early backer of Hedera Dx, which raised a €15 million Series A in May 2025. Hedera Dx brings liquid-biopsy testing into hospital laboratories, using circulating tumour DNA and other molecular data to profile cancers and help match patients to targeted therapies.

Heal Capital

European healthcare VC investing in technology that improves clinical delivery and health-system workflows.

Stage: Pre-Seed · Seed · Series A
Sector / Focus: Healthtech · Medtech · Clinical AI
Investment markets: Germany · United Kingdom · Europe
Investor type: VC

Relevant investment

Heal Capital led Hypervision Surgical’s £17 million Series A in April 2026. Hypervision combines hyperspectral imaging and AI to analyse tissue in real time during surgery, helping clinicians distinguish tissue types and assess perfusion without injected contrast agents.

redalpine

Pan-European VC investing across science, software and deep technology.

Stage: Seed · Series A
Sector / Focus: Deep Tech · Healthtech · AI
Investment markets: Switzerland · United Kingdom · Luxembourg
Investor type: VC

Relevant investment

redalpine is an existing investor in Hypervision Surgical and participated in its £17 million Series A in 2026. Hypervision uses hyperspectral imaging and AI to turn reflected light into real-time tissue maps for surgeons. redalpine also led Helical’s $10 million seed round in 2026; Helical turns biological foundation models into reproducible in-silico drug-discovery workflows for pharmaceutical teams. Together, the investments show exposure to both clinical image interpretation and data-intensive life-science infrastructure.

Kima Ventures

Early-stage technology investor backing startups in Europe and internationally.

Stage: Seed · Series A
Sector / Focus: Technology · Healthtech · Diagnostics
Investment markets: France · Europe
Investor type: VC

Relevant investment

Kima Ventures participated in One Biosciences’ €15 million Series A in July 2025. One Biosciences is developing clinical-grade single-cell tumour profiling that combines transcriptomic data and AI to support treatment decisions, patient selection and drug development.

GO CAPITAL

French early-stage investor focused on innovation-led technology companies.

Stage: Seed · Series A
Sector / Focus: Deep Tech · Healthtech · Medtech
Investment markets: France
Investor type: VC

Relevant investment

GO CAPITAL co-led BrightHeart’s €11 million Series A in January 2026. BrightHeart’s B-Right platform applies AI to prenatal ultrasound, helping sonographers check whether key fetal-heart views have been captured and flagging patterns associated with severe congenital heart defects.

QantX

UK early-stage investor focused on high-impact innovation in the South and South West of England.

Stage: Pre-Seed · Seed
Sector / Focus: Diagnostics · Healthcare · Deep Tech
Investment markets: United Kingdom
Investor type: VC

Relevant investment

QantX led iFAST Diagnostics’ £2 million round in 2023 and remained an investor as the startup later raised additional capital. iFAST is developing rapid antimicrobial-susceptibility testing that can identify which antibiotics are likely to work against an infection within hours rather than days, supporting faster treatment decisions and antimicrobial-resistance management.

Asabys Partners

Healthcare-focused VC investing across biopharma, medtech and digital health.

Stage: Seed · Series A
Sector / Focus: Medtech · Diagnostics · Digital Health
Investment markets: Spain · Belgium
Investor type: VC

Relevant investment

Asabys co-led Quibim’s $50 million Series A in January 2025. Quibim develops AI models that extract quantitative imaging biomarkers from MRI, CT and PET scans to support disease characterisation, patient stratification and treatment decisions across areas including oncology and neurology.

Amadeus Capital Partners

VC investing in deep tech, healthtech and medical innovation from pre-seed through Series A.

Stage: Pre-Seed · Seed · Series A
Sector / Focus: Healthtech · Medtech · Molecular Diagnostics
Investment markets: Spain · United Kingdom
Investor type: VC

Relevant investment

Amadeus Capital Partners participated in Quibim’s $50 million Series A in 2025. Quibim’s software converts medical images into quantitative biomarkers, giving clinicians and drug developers more structured information than conventional image review alone.

APEX Ventures

European VC investing in early-stage deep tech and medical technology.

Stage: Seed · Series A
Sector / Focus: Medtech · Deep Tech · Diagnostics
Investment markets: Spain · France · United Kingdom
Investor type: VC

Relevant investment

APEX Ventures also participated in Quibim’s $50 million Series A in 2025. The investment gives APEX exposure to AI-enabled imaging diagnostics that extract reproducible biomarkers from standard MRI, CT and PET scans and use them in precision-medicine workflows.

Methodology

DealBio builds investor lists using structured investor research, demonstrated investment activity and current public verification where needed. The methodology highlights investors with evidenced relevance to the article’s sector, stage and geography.

Relevant investment

Relevant investment

Relevant investment

Relevant investment

Relevant investment

Relevant investment

Relevant investment

Relevant investment

Relevant investment

Relevant investment

Methodology

Get the DealBio Pulse